Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS they serve since 1997
Meetings & Education
Financial Advocacy & Patient Assistance
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
Hurricane Florence Relief
SCOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Ibrutinib Plus Rituximab for Rare Blood Cancer
On August 27, AbbVie announced that the FDA has approved ibrutinib (Imbruvica) (Pharmacyclics, LLC) plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL). This approval represents the first and only chemotherapy-free combination treatment specifically indicated for the disease.
Read the full AbbVie corporate press release here.
Tweets by OSSatACCC